MENS (Jyong Biotech) Tax Expense: $0.00 Mil (TTM As of Dec. 2025)


MENS Jyong Biotech Ltd MENS
10 GF Score
Price $2.22
! 3 Warning Signs
View Full Analysis

What is Jyong Biotech Tax Expense?

Jyong Biotech MENS +6.47% 10 Tax Expense is $0.00 Mil as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Jyong Biotech's tax expense for the months ended in Dec. 2025 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.


Jyong Biotech  (NAS:MENS) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Jyong Biotech Tax Expense Related Terms


Jyong Biotech Tax Expense Historical Data

* Premium members only.

The historical data trend for Jyong Biotech's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jyong Biotech Tax Expense Chart

Jyong Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
0.00 0.00 0.00 0.00 0.00

Jyong Biotech Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
MENS
10GF Score
Jyong Biotech Ltd MENS
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jyong Biotech Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $0.00 Mil mean?
Jyong Biotech (MENS) has a Tax Expense of $0.00 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Jyong Biotech and its competitors.
Is Jyong Biotech's Tax Expense too high?
Jyong Biotech's current Tax Expense is $0.00 Mil. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's Tax Expense compare to ENLV and CNTB?
Jyong Biotech's Tax Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Jyong Biotech and its competitors. Jyong Biotech's current Tax Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current Tax Expense of $0.00 Mil. The current Tax Expense is $0.00 Mil. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Jyong Biotech (MENS), the current Tax Expense is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jyong Biotech Business Description

Address Xintai 5th Road, 23F-3, No. 95, Section 1, Xizhi district, New Taipei, TWN, 221
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score

Get the complete analysis for MENS

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.22
Price